lilly oral glp-1 FDA just approved orforglipron (Foundayo), Eli Lilly's receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest ADA: Lilly makes its case

Previously prescribed to treat blood sugar spikes in diabetes patients, glucagon-like peptide 1 (GLP-1) drugs stimulate release of insulin, keeping blood sugar levels low

If you become vitamin B12 deficient, it can affect your memory and cognition

If you want the fully illustrated version, use our guide to injecting peptides

Research Note: In a gene-array analysis of skin cells reviewed by Pickart and Margolina in the International Journal of Molecular Sciences (2018), GHK produced a change of 50% or greater in expression for 31.2% of the human genes tested, with about 59% of those genes upregulated and 41% suppressed (Pickart & Margolina, 2018)

doi: 10.1016/s0891-5849(97)00286-4 239 Santos Duarte LanaJ